fig1

From: Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study

Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study

Figure 1. Protocol of single dose rituximab as induction therapy for aggressive NMOSD patients in Kuala Lumpur Hospital, Malaysia. NMOSD: neuromyelitis optica spectrum disorder; IPND: international panel for neuromyelitis optica diagnosis

Neuroimmunology and Neuroinflammation

ISSN 2349-6142 (Online) 2347-8659 (Print)

[email protected]

Navigation

Sitemap

Navigation

Sitemap

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Discover Content

Strategic Collaborators

Follow OAE

Privacy Cookies Terms of Service